176MO ORCA-010 oncolytic therapy: Inducing tumor-specific immune responses and activation of tumor microenvironment in treatment-naïve prostate cancer
interactions.WES analysis showed LOH of one HLA-II isotype in 10/76 non-acral cutaneous melanoma samples (2/9 patients), and only in 1/52 acral/mucosal samples (1/5 patients), suggesting immune editing may drive HLA-II loss. Conclusions:Our findings indicate a link between melanoma dedifferentiation, CD4+ TIL recognition via HLA-DR, and HLA-II loss.Recognition of HLA-II+ melanomas is preferentially mediated via HLA-DR, but LOH might impact neoantigen presentation, leading to immune evasion.
Authors
- T.D. de Gruijl
- Kenneth Jansz
- Richard Casey
- Amitai Abramovitch (ORCID: https://orcid.org/0000-0001-9640-0970)
- Reza Nadafi (ORCID: https://orcid.org/0000-0002-6769-4145)
- T. Brachtlová
- Peter Incze (ORCID: https://orcid.org/0000-0003-2630-7812)
- B. Shayegan
- Wanli Dong (ORCID: https://orcid.org/0000-0003-1000-3814)
- Victor W. van Beusechem
- Jonathan Giddens
Institutions
- Scarborough Health Network (CA)
- Joseph Brant Hospital (CA)
- Oakville-Trafalgar Memorial Hospital (CA)
- Brampton Civic Hospital (CA)
- Amsterdam University Medical Centers (NL)
- Expertise Center Vocational Education (NL)
- St. Joseph’s Healthcare Hamilton (CA)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100929
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Francis Crick Institute
- Gordon and Rose McAlpine Foundation for Neuroscience Research
- Cancer Research UK
- National Institute for Health and Care Research
- Novo Nordisk
- H. Lundbeck A/S